1. Mathew J, Sleight P, Lonn E et al. and HOPE Investigators: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104:1615–21.
2. Sowers JR and Bakris GL: ASH position paper: treatment of hypertension in patients with diabetes – an update. J Clinical Hypertension 2008, 10:707-13.
3. Chaturvedi N, SjolieAK, Stephenson JM, et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998, 351:28-31.
4. Yusuf S, Gerstein H, Hoogwerf B, et al. and HOPE Investigators: Ramipril and the development of diabetes. JAMA 2001, 286:1882-5.
5. Trevisan, R., et al., Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. Diabetes, 1990. 39(3): p. 289-98.
6. Barzilay JI, Davis BR, Cutler JA, et al. and ALLHAT Collaborative Research Group: Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006, 166(20):2191-201.
7. Wing LM, Reid CM, Ryan P, et al. and the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Eng J Med 2002, 348:583-92.
8. Yusuf S, Teo KK, Pogue J, et al. and the ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Eng J Med 2008, 358:1547-59.
9. Pfeffer MA, McMurray JJV, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Eng J Med 2003, 349:1893-906.
10. Yusuf S, Teo KK, Pogue J, et al. and the ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Eng J Med 2008, 358:1547-59.
11. Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-65
12. Lindholm LH, Hansson L, Ekbom T, et al. and the STOP Hypertension-2 Study Group: Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens 2000, 18:1671-5.
13. Beckett NS, Peters R, Fletcher AE, et al. and the HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. N Eng J Med 2008, 358:1887-98.
14. Ernst ME, Carter BL, Goerdt CJ, et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352-8.
15. Jamerson K, Weber MA, Bakris GL, et al. and the ACCOMPLISH trial investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Eng J Med 2008, 359:2417-28
16. UK Prospective Diabetes Study Group: Efficacy of atenolol ad captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713-20
17. Lindholm LH, Ibsen H, Dahlof B, et al. and the LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-10.
18. Pessina AC, Ciccariello L, Perrone F, et al.: Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutrition, Metabolism and Cardiovascular Disesases 2006, 16:137-47.
19. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 286:1967-75
20. Hillebrand U, Lang D, Telgmann RG, et al.: Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study. J Hypertens 2009, 27:517-26.
21. Khakam Z, Yasmin, McEniery CM, et al.: A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008, 26:351-6.
22. Sowers JR, Whaley-Connell A, Epstein M: Narrative Review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776-83.
23. Lane DA, Shah S, Beevers DG: Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007, 25:891-4.
24. Schmieder RE, Philipp T, Guerediaga J, et al.: Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009, 27:1493-1501
25. Schmieder RE, Philipp T, Guerediaga J, et al.: Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009, 119:417-25
26. Solomon SD, Appelbaum E, Manning WJ, et al. and the Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators: Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530-7.
27. Yamamoto E, Kataoka K, Dong Y-F, et al.: Aliskiren inhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009, 54:633-8
28. Weber MA, Black H, Bakris G, et al.: A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1423-31.
29. Takenouchi Y, Kobayashi T, Matsumoto T, et al.: Possible involvement of Akt activity in endothelial dysfunction in type 2 diabetic mice. J Pharmacol Sci 2008, 106:600-8
30. Strazzullo P, Kerry SM, Barbato A, et al.: Do statins reduce blood pressure?: A meta-analysis of randomized, controlled trials. Hypertension 2007, 49:792-8